Senores Pharmaceuticals Q1 FY26: Income ₹138 Cr, PAT ₹21 Cr

Stock snapshot and why the results mattered

Senores Pharmaceuticals’ latest quarterly update drew attention as the company reported sharp year-on-year growth in revenue and profit for Q1 FY26. In one market snapshot shared in the input, the stock was at ₹1,381.9, up ₹45.5 or 3.40%. Another cited market update showed the share trading at ₹690 on BSE at 12:27 PM, up 13.16%, highlighting that price quotes in the sources were from different points in time or feeds. The core trigger for the move was the company’s Q1 FY26 earnings release and investor communication. The quarter also included updates on ANDA approvals, product commercialisation, and CDMO additions. Together, these data points helped frame how the company is scaling across regulated, emerging and India branded generics markets.

Q1 FY26 headline numbers: income, EBITDA and PAT

For Q1 FY26, Senores Pharmaceuticals reported consolidated total income of ₹138.0 crore, up 72% year-on-year, as stated in the media release and investor highlights. EBITDA rose 60% year-on-year to ₹34.2 crore. Profit after tax (PAT) increased 95% year-on-year to about ₹21.2 crore, as cited in the company’s Q1 FY26 highlights. The same set of disclosures also mentioned an EBITDA margin of 24.8% for the quarter, compared with 26.5% in the year-ago period. Revenue from operations for Q1 FY26 was reported at ₹130.3 crore, up 64% from ₹79.5 crore a year ago. The company also flagged positive operating cash flow during the quarter.

Segment mix: regulated markets remained the largest driver

Regulated markets were the largest contributor in Q1 FY26, accounting for 65% of total revenue at ₹90.1 crore, as stated in the Q1 communication. Another line in the inputs also put regulated markets revenue at about ₹90 crore, up 69% year-on-year. Emerging markets revenue was reported at ₹29 crore, growing 32% year-on-year. The branded generics business in India was reported at ₹8 crore for Q1 FY26, with the company describing it as seeing strong momentum. Management commentary in the transcript also indicated expectations that regulated markets would continue contributing around 60% to 70% of total revenue, with emerging markets around 30%. These figures underline that the current scale-up is still led by regulated markets, with branded generics and CDMO positioned as incremental growth levers.

Operational updates: ANDA approvals, launches, and CDMO additions

Alongside the financial numbers, Senores Pharmaceuticals reported multiple execution milestones for the quarter. The company received ANDA approvals for four products during Q1 FY26. It also commercialised two products in the regulated markets and indicated its total commercialised portfolio at 24 products as of June 30, 2025. The company’s approved ANDA portfolio was referenced at about 70 by the end of the quarter in management commentary. On the CDMO/CMO side, Senores added five new products, taking the total to 27 products. In emerging markets, the company reported registration approvals for 23 products and a total portfolio of 308 products.

Cash flow and subsidiary stake: what changed in the quarter

The company highlighted cash flow from operations of ₹11 crore for Q1 FY26 and stated an intent to maintain a positive trajectory for FY26. In the same investor highlights, it also reported an increase in its direct stake in Havix to 73% from 66.6% in December 2024. Management indicated a plan to increase this stake to 78% by the end of the quarter. These disclosures are relevant because rapid revenue growth can strain working capital, making cash conversion an important watch point. Senores’ statement on operating cash flow aimed to address that concern directly, at least for the quarter reported.

Guidance and management commentary for FY26

In the management commentary included in the inputs, the company reiterated confidence of delivering about 50% growth in top line and about 100% growth in PAT for FY26 over FY25. It also discussed a full-year revenue guidance band of ₹600 crore to ₹650 crore. The commentary further referenced an annualised stable EBITDA margin of about 25% to 26% as a target. Separately, the transcript also mentioned an expectation of profitability stabilising at around 15% to 17% on a sustainable annualised basis, reflecting that multiple margin metrics were discussed across communications. The Q1 EBITDA margin was cited at 24.8%, slightly below the 25% to 26% range mentioned. The company also said the branded generics business is expected to surpass ₹50 crore in FY26.

Subsequent quarters referenced: Q2, Q3, Q4 and nine-months update

Beyond Q1, the provided material also contained figures for later quarters and a nine-month update, giving a broader context of FY26 performance. For Q2 FY26, the company reported consolidated revenue of ₹162 crore, EBITDA of ₹50 crore, and PAT of ₹30 crore, according to the PRNewswire release dated Nov. 7, 2025. It also said H1 FY26 revenue was ₹300 crore, EBITDA ₹84 crore, and PAT ₹51 crore, with operating cash flow of ₹31.4 crore. Another set of figures in the input cited Q3 FY26 income of about ₹175 crore, EBITDA of about ₹54 crore, and PAT of about ₹34 crore, along with a release date of January 20, 2026. The same update cited nine-month FY26 revenue of ₹474 crore, EBITDA of ₹138 crore, PAT of ₹84 crore, and operating cash flow of ₹151 crore. For Q4 FY26, revenue from operations was listed at ₹175.19 crore and total income at ₹182.86 crore, with a note that a media release highlighted total income at ₹190 crore including other operating income.

Key numbers table (all amounts in ₹ crore)

Another quarterly statement shared in the input (all figures in ₹ crore)

The input also contained a separate quarterly results table with a smaller “Net Sales” line item and a large “Other Income” line item across quarters. The table reported Net Sales of ₹11.86 crore (Mar 2025), ₹19.82 crore (Jun 2025), ₹35.33 crore (Sep 2025), ₹28.76 crore (Dec 2025), and ₹36.81 crore (Mar 2026). In the same table, Profit After Tax was ₹2.02 crore (Mar 2025), ₹2.70 crore (Jun 2025), ₹6.43 crore (Sep 2025), ₹2.65 crore (Dec 2025), and ₹8.48 crore (Mar 2026). Other income in that statement ranged from ₹8.39 crore to ₹22.19 crore across the listed quarters. These figures were presented in the source as “All Figures in Cr.” and are reproduced here as provided, without assuming how they reconcile to the consolidated income figures cited elsewhere in the input.

Market impact and what investors tracked

From the disclosures provided, investors had three immediate items to track: the pace of regulated market scaling, the expansion in product approvals and launches, and operating cash flow. The quarter showed a large regulated market contribution at around ₹90 crore and a stated 65% revenue share, which is consistent with management’s comment that regulated markets could remain 60% to 70% of revenue. Operationally, four ANDA approvals and two product commercialisations in the quarter were positioned as incremental drivers for the regulated market portfolio. Cash flow from operations at ₹11 crore in Q1 FY26 was highlighted as a sign of improved cash conversion during growth. The company’s stated FY26 guidance of ₹600 crore to ₹650 crore in revenue and the margin targets became reference points for future quarters.

Conclusion

Senores Pharmaceuticals’ Q1 FY26 update combined strong year-on-year growth in income, EBITDA and PAT with multiple portfolio and execution milestones, including ANDA approvals and CDMO additions. The company also highlighted positive operating cash flow and reiterated FY26 guidance of ₹600 crore to ₹650 crore revenue alongside profitability targets referenced in management commentary. Subsequent-quarter figures included in the provided material indicate that investors were also tracking momentum through Q2, Q3 and Q4 FY26 and the nine-month snapshot. The next key checkpoints, based on the same disclosures, remain delivery against the full-year guidance band and continued execution on approvals, launches and commercialisation.